Guerrero, Ana http://orcid.org/0000-0002-4622-9201
Innes, Andrew J. http://orcid.org/0000-0003-0918-8882
Roux, Pierre-François http://orcid.org/0000-0002-0695-4206
Buisman, Sonja C.
Jung, Johannes
Ortet, Laura
Moiseeva, Victoria
Wagner, Verena http://orcid.org/0000-0003-2604-0759
Robinson, Lucas
Ausema, Albertina
Potapova, Anna
Perdiguero, Eusebio
Weersing, Ellen
Aarts, Marieke http://orcid.org/0000-0003-1482-5866
Martin, Nadine
Wuestefeld, Torsten
Muñoz-Cánoves, Pura
de Haan, Gerald http://orcid.org/0000-0001-9706-0138
Bischof, Oliver
Gil, Jesús http://orcid.org/0000-0002-4303-6260
Funding for this research was provided by:
Cancer Research UK (C15075/A28647)
RCUK | Medical Research Council (MC_U120085810)
LifeArc (n/a)
Article History
Received: 25 August 2020
Accepted: 4 August 2022
First Online: 13 September 2022
Competing interests
: J.G. has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma and Merck KGaA. Pfizer and Unity Biotechnology have funded research in J.G.’s laboratory (unrelated to the work presented here). J.G. owns equity in Geras Bio. J.G. and A.G. are named inventors in an MRC patent and J.G. is a named inventor in other Imperial College patents, both related to senolytic therapies (the patents are not related to the work presented here). T.W. is scientific co-founder of, and holds stakes in, Cargene Therapeutics, which develops nucleic-acid therapeutics for liver diseases (unrelated to the work presented here). The remaining authors declare no competing interests.